• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TauRx receives $111.8M from Genting for Alzheimer's trials

TauRx receives $111.8M from Genting for Alzheimer's trials

November 20, 2012
CenterWatch Staff

TauRx Pharmaceuticals of Singapore has received a further equity investment of $31.5 million from Genting Management (GMS), a Singapore-based subsidiary of Genting Berhad.

The amount represents the first tranche of a total investment of $111.8 million by GMS in TauRx in exchange for a 20% equity stake in the pioneering pharmaceutical company. The completion of the remaining $80.3 million investment by GMS is expected before the year end.

"This investment by GMS affirms Genting's confidence in TauRx and will be directed to the conduct of our pivotal global phase III clinical trials in mild to moderate Alzheimer's disease with LMTX, TauRx's Tau Aggregation Inhibitor (TAI),” said Claude Wischik, executive chairman and co-founder of TauRx.

The drug is the first TAI to be tested in late stage clinical trials. The phase II trial in over 300 patients with an earlier version of the drug showed a 90% reduction in the rate of disease progression over two years, a result also supported by functional brain imaging.

The first study in the phase III program will involve 833 people with mild to moderate Alzheimer's disease over 12 months, while the second study will include 500 people with mild Alzheimer's disease over 18 months. A third, smaller study will aim to confirm treatment benefit in FrontoTemporal Dementia in 180 subjects over 12 months. The clinical trials will be conducted in parallel and on a global basis.

In connection with the investment, TauRx appointed Genting Berhad executives to its board of directors: Tan Sri Lim Kok Thay, chairman and CEO of Genting Berhad, and Tan Kong Han, president and COO of Genting Berhad.

Furthermore, as part of the share subscription by GMS, TauRx and GMS will form a joint venture which will leverage on the Genting Group's network and presence in Asia and which will focus on redefining healthcare delivery for Alzheimer's and early cognitive impairment in Asia.

"The joint venture's business model would redefine healthcare delivery for one of the most costly medical conditions of our time—Alzheimer's disease, as it integrates each step in the continuum of healthcare delivery from the development of clinics specializing in early detection, through the management of cognitive impairment with innovative diagnostic tools to the early intervention with LMTX,” said Wischik.

LMTX is a second-generation TAI that targets the Tau tangles and their precursors, dissolving them in order to halt harmful effects on memory. The joint venture would have the potential to create a clinic-based assessment and treatment capability that does not impact on TauRx's ability to offer distribution and marketing rights to conventional pharmaceutical partners active in Asia. 

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing